• 1
    Attinger AB, Hermann BP, eds. Psychiatric issues in epilepsy. Neurology 1999;suppl 2:53.
  • 2
    Monaco F, Robertson MR, eds. Mood disturbances, psychoses and epilepsy. Epilepsia 1999;40:suppl 10.
  • 3
    Torta R, Keller R. Behavioural, psychotic and anxiety disorders in epilepsy: etiology, clinical features and therapeutical implications. Epilepsia 1999;40(suppl 10):220.
  • 4
    Torta R, Borio R, Cicolin A, et al. Therapeutic aspects of depression and epilepsy: new vs old antidepressant drugs. 8th Congress of Association of European Psychiatrists. Annual Meeting of the Royal College of Psychiatrists. London, 1996: Abstract 57.
  • 5
    Buterbaugh GG. Effect of drugs modifying central serotonergic function on the response of extensor and nonextensor rats to maximal electroshock. Life Sci 1978;23:2393240.
  • 6
    Dayley JW, Yan QS, Mishra PK. Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats. J Pharmacol Exp Ther 1992;33:540.
  • 7
    Leander JD. Fluoxetine, a selective serotonin-uptake inhibitor, enhances the anticonvulsant effects of phenytoin, carbamazepine and ameltolide. Epilepsia 1992;33:5736.
  • 8
    Prendville S, Gale K. Anticonvulsant effect of fluoxetine on focally evoked limbic motor seizures in rats. Epilepsia 1993;34:3814.
  • 9
    Starr MS. The role of dopamine in epilepsy. Synapse, 1996;22:1599.
  • 10
    Burke K, Chandler CJ, Starr BS, et al. Seizure promotion and protection by D-1 and D-2 dopaminergic drugs in the mouse. Pharmacol Biochem Behav 1990;36:72933.
  • 11
    Sultan S, Chouinard G, Beaudry P. Antiepileptic drugs in the treatment of neuroleptic-induced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:4318.
  • 12
    Oliver AP, Luchins DJ, Wyatt RJ. Neuroleptic-induced seizures: an in vitro technique for assessing relative risk. Arch Gen Psychiatry 1982;39:2069.
  • 13
    Brodtkorb E, Sand T, Strandjord RE. Neuroleptic and antiepileptic treatment in the mentally retarded. Seizure 1993;2:20511.
  • 14
    Alldredge BK. Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 1999;53(suppl 2):S6875.
  • 15
    Burke K, Chandler CJ, Starr BS, et al. Seizure promotion and protection by D-1 and D-2 dopaminergic drugs in the mouse. Pharmacol Biochem Behav 1990;36:72933.
  • 16
    Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:8796.
  • 17
    Ogren SO, Pakh B. Effects of dopamine D1 and D2 receptor agonists and antagonists on seizures induced by chemoconvulsants in mice. Pharmacol Toxicol 1993;72:21320.
  • 18
    Kleinlogel H. Spontaneous EEG paroxysms in the rat: effects of psychotropic and alpha-adrenergic agents. Neuropsychobiology 1985;13:20613.
  • 19
    Motta E. Epilepsy and hormones. Neurol Neurochir Pol 2000;33(suppl 1):316.
  • 20
    Torta R, Biggio G. Gli ansiolitici. In: BizziB, TrabucchiM, eds. Farmacoterapia. Torino: UTET, 1995:93142.
  • 21
    Maurice T, Phan VL, Urani A, et al. Neuroactive neurosteroids as endogenous effectors for the sigma1 (sigma1) receptor: pharmacological evidence and therapeutic opportunities. Jpn J Pharmacol 1999; 81:12555
  • 22
    Post RM, Kopanda RT. Cocaine, kindling and psychosis. Am.J Psychiatry 1976;133: 62734.
  • 23
    Post RM. Lidocaine-kindled limbic seizures: behavioural implications. In: Wada JA, ed. Kindling 2. New York: Raven Press, 1981:149–60.
  • 24
    Post RM, Rubinow DR, Ballanger JC. Conditioning, sensitiziation and kindling: for the course of affective illness. In: PostRM, BalJC, eds. Neurobiology of mood disorders. Baltimore: Williams & Wilkins, 1984:43266.
  • 25
    Adamec RE. Does kindling model anything clinically relevant? Biol Psychiatry 1990;27:24979.
  • 26
    Monaco F. Cognitive effects of vigabatrin: a review. Neurology 1996;47(suppl 1):S611.
  • 27
    Monaco F, Torta R, Cicolin A, et al. Lack of association between vigabatrin and impaired cognition. J Int Med Res 1997;25:296301.
  • 28
    George B, Kulkarni SK, Protective effect of clozapine against pentylenetetrazol convulsions and kindling. Methods Fund Exp Clin Pharmacol 1998;20:395–401.
  • 29
    Stevens JR, Denney D, Szot P. Sensitization with clozapine: beyond the dopamine hypothesis. Biol Psychiatry 1997;42:77180.
  • 30
    Malow BA, Reese KB, Sato S, et al. Spectrum of EEG abnormalities during clozapine treatment. Electroencephalogr Clin Neurophysiol 1994;91:20511.
  • 31
    Toth P, Frankenburg FR. Clozapine and seizures: a review. Can J Psychiatry 1994;39:2368.
  • 32
    Owens MJ, Risch SC. Atypical antipsychotics. In: SchatzbergAF, NemeroffCB, eds. Textbook of psychopharmacology. Washington, DC: American Psychiatric Association, 1998:20544
  • 33
    Tsuchiya H, Kawahara R, Tanaka Y. Generalized seizures during treatment of schizophrenia with zotepine. Yonago Acta Med 1986;29:10311.
  • 34
    Manmaru S. Five cases of schizophrenia with convulsive seizures during zotepine administration. Seishin Igaku 1985;27:5970.
  • 35
    Hori M, Suzuki T, Sasaki M. Convulsive seizures in schizophrenic patients induced by zotepine administration. Jpn J Psychiatry Neurol 1992;46:1617.
  • 36
    Bymaster FP, Nelson DL, DeLapp NW, et al. Antagonism by olanzapine of dopamine D1, serotonin 2, muscarinic, histamine 1, and alpha 1-adrenergic receptors in vitro. Schizophr Res 1999;37:10722.
  • 37
    Kennedy JS, Bymaster FP, Basson BR, et al. Tran PV the comparative peripheral anticholinergic-like adverse event profiles of olanzapine and risperidone. Prim Care Comp J Clin Psych 2000;2:1226.
  • 38
    Marx CE, Duncan GE, Gilmore JH, et al. Olanzapine increases allopregnanolone in the rat cerebral cortex. Biol Psychiatry 2000;47:10004.
  • 39
    Long PW. Olanzapine drug monograph. Internet Mental Health, 1996.
  • 40
    Monaco F, Cicolin A. Interactions between anticonvulsant and psychoactive drugs. Epilepsia 1999;40(suppl 10):S716.
  • 41
    Meldrum BS, Turski L, Schwarz M, et al. Anticonvulsant action of 1,3-dimethyl-5-aminoadamantane: pharmacological studies in rodents and baboon, Papio papio. Naunyn Schmiedeberg Arch Pharmacol 1986;332:937.
  • 42
    Kleinrok Z, Czuczwar SJ, Kozicka M. Effect of dopaminergic and GABA-ergic drugs given alone or in combination on the anticonvulsant action of phenobarbital and diphenylhydantoin in the electroshock test in mice. Epilepsia 1980;21:51929.
  • 43
    Hoffman A, Afargan M, Backon J, et al. The anticonvulsant effect of deprenyl on pentylenetetrazol-induced seizures in Lewis rats. Int J Neurosci 1997;90:22332.
  • 44
    Trimble MR, Ring HA, Schmitz B. Neuropsychiatric aspects of epilepsy. In: FogelBS, SchifferRB, RaoSM, eds. Neuropsychiatry. Baltimore: Williams & Wilkins, 1996:771803.
  • 45
    Luchins DJ, Oliver PA, Wyatt RJ. Seizures with antidepressants: an in vitro tecnique to assess relative risk. Epilepsia 1984;25:2532.
  • 46
    Trimble MR, Anlezark G, Meldrum B. Seizure activity in photo-sensitive baboons following antidepressant drugs and the role of serotoninergic mechanism. Psychopharmacology 1977;51:15964.
  • 47
    Frommer DA, Culig KW, Marx JA, et al. Tricyclic antidepressant overdose: a review. JAMA 1987;257:5226.
  • 48
    Edwards JG, Wheal HV. Assessment of epileptogenic potential experimental, clinical and epidemiological approaches. J Pharmacol 1992;6:20413.
  • 49
    Lambert MV, Robertson MM. Depression in epilepsy: aetiology, phenomenology and treatment. Epilepsia 1999;40(suppl 10):S2147.
  • 50
    Skowron DM, Stimmel GL. Antidepressant and the risk of seizures. Pharmacotherapy 1992;12:1822.
  • 51
    Favale E, Rubino V, Mainardi P, et al. Anticonvulsant effect of fluoxetine in humans. Neurology 1995;45:19267.
  • 52
    Troisi A, Vicario E, Nuccetelli F, et al. Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy. Pharmacopsychiatry 1995;28:736.
  • 53
    Tata MR, Lettieri B, Vicario C. Osservazioni su di un caso con inaspettato stato di male convulsivo: ruolo della fluoxetina. Boll Lega Ital Epil 1983;84:167.
  • 54
    Weber JJ. Seizure activity associated with fluoxetine therapy. Clin Pharm 1989;8:2968.
  • 55
    Ware MR, Stewart RB. Seizures associated with fluoxetine therapy. Ann Pharmacother 1989;23:428.
  • 56
    Deahl M, Trimble MR. Serotonin reuptake inhibitors, epilepsy and myoclonus. Br J Psychiatry 1991;159:4335.
  • 57
    Gigli GL, Diomedi M, Troisi A, et al. Lack of potentiation of anticonvulsant effect by fluoxetine in drug-resistant epilepsy. Seizure 1994;3:2214.